MiNK Therapeutics, Inc.
NASDAQ: INKT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jennifer S. Buell
- Employees
- 23
- Headquarters
- New York City, United States
- IPO year
- 2021
- Market cap
- $60.3M
- Website
- https://minktherapeutics.com
Loading INKT…
Loading profile data…Frequently asked questions about INKT
What does MiNK Therapeutics, Inc. (INKT) do?
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for comb...
Where does INKT trade?
MiNK Therapeutics, Inc. (INKT) trades on the NASDAQ Capital Market.
What sector is INKT in?
MiNK Therapeutics, Inc. (INKT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of MiNK Therapeutics, Inc.?
Jennifer S. Buell is the chief executive officer of MiNK Therapeutics, Inc. (INKT).
Where is MiNK Therapeutics, Inc. headquartered?
MiNK Therapeutics, Inc. is headquartered in United States.
Does INKT pay a dividend?
MiNK Therapeutics, Inc. (INKT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did INKT go public?
MiNK Therapeutics, Inc. (INKT) completed its initial public offering in 2021.